港股異動 | 錦欣生殖(1951.HK)盤初急升至7% 將於本月30日放榜 此前發盈喜
格隆匯3月27日丨錦欣生殖(1951.HK)今日股價高開急漲,現升6.93%,報8.79港元,暫成交3051萬港元,最新總市值213.7億港元。錦欣生殖(01951.HK)3月30日董事會考慮及批准年度業績。此前,公司預期年度純利大幅增加逾90%,主要是由於集團於2018年12月收購美國業務;及集團IVF(體外受精)取卵週期及利潤率的增加。瑞信報告稱,引述管理層透露,維持今年內地業務收入增長約15%的指標,也維持內地業務2020/2021財年收入將達13.45億及18.95億元人民幣的預測。並維持“跑贏大市”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.